Regeneron Pharma Earnings, Revenue Beat in Q2
2022.08.03 13:54
Regeneron Pharma Earnings, Revenue Beat in Q2
Investing.com – Regeneron Pharma (NASDAQ:REGN) reported on Wednesday second quarter earnings that beat analysts’ forecasts and revenue that topped expectations.
Regeneron Pharma announced earnings per share of $9.77 on revenue of $2.86B. Analysts polled by Investing.com anticipated EPS of $8.6 on revenue of $2.79B.
Regeneron Pharma shares are down 7% from the beginning of the year, still down 23.07% from its 52 week high of $747.42 set on April 8. They are outperforming the S&P 500 which is down 14.16% from the start of the year.
Regeneron Pharma follows other major Healthcare sector earnings this month
Regeneron Pharma’s report follows an earnings beat by UnitedHealth on July 15, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on July 19 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
